Strong Collaboration is Essential for Radiation Oncologists and Other Experts

News
Video

As a radiation oncologist, James B. Yu, MD, MHS, FASTRO, works with urologists, medical oncologists, radiologists, pathologists, physicists, and health services researchers.

As an expert in genitourinary cancers, he spoke about working with urologists as they are often the main “proceduralists” for diagnosing cancer, and medical oncologists as they would be the next step for the patient, after radiation fails them. When it comes to research, as Yu has a specific interest in that aspect of work, he collaborates with radiologists, pathologists, physicists, and health services researchers. All of this comes along with working with patients.

As Yu, professor in the Department of Radiation Oncology and Applied Sciences, leader of the Genitourinary Radiation Oncology Program at Dartmouth Hitchcock Medical Center, and radiation oncology editorial advisory board member of the Journal ONCOLOGY®, stated, “radiation oncologists are at the end of the referral stream, so if you can’t collaborate with people or respond to referring physicians, then you’re not going to do very well in radiation oncology.”

Transcript:

Radiation oncologists are at the end of the referral stream, so if you can’t collaborate with people or respond to referring physicians, then you’re not going to do very well in radiation oncology. In genitourinary radiation oncology, the urologists are the ones who are the main proceduralists. They refer patients [to us], they do the diagnosis, and [they] collaborate [with us] in academic research. Medical oncologists are critical if radiation fails or if you want to do novel combination therapies, and they also have internal medicine training, which the vast majority of us don’t. Those 2 groups are critical to any genitourinary radiation oncology practice.

Then, in research, having good radiologists and pathologists facilitates your research tremendously. Physicists, as well, are a huge part of radiation oncology—they’re often the ones thinking of the most novel technical innovations. In the work that I do in research, health outcomes and health services researchers and people in public health [are important]—my mentor in research is an internal medicine physician who has an interest in cancer. The more people you can work with outside of radiation oncology, the more interesting your world is going to be, and the more fulfilling [it will be].

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Related Content